Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Expands By 188.2%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 843,600 shares, an increase of 188.2% from the February 28th total of 292,700 shares. Based on an average daily trading volume, of 685,500 shares, the days-to-cover ratio is currently 1.2 days. Currently, 34.6% of the shares of the company are sold short.

CERo Therapeutics Price Performance

Shares of NASDAQ:CERO traded down $0.03 during trading on Friday, reaching $0.74. 107,823 shares of the company’s stock traded hands, compared to its average volume of 395,779. CERo Therapeutics has a 12 month low of $0.66 and a 12 month high of $376.00. The company has a 50 day moving average of $1.65 and a 200-day moving average of $7.32.

Hedge Funds Weigh In On CERo Therapeutics

A hedge fund recently raised its stake in CERo Therapeutics stock. Avantax Planning Partners Inc. increased its stake in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) by 89.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,585,151 shares of the company’s stock after buying an additional 1,224,021 shares during the quarter. Avantax Planning Partners Inc. owned about 172.00% of CERo Therapeutics worth $155,000 at the end of the most recent quarter. Institutional investors and hedge funds own 29.64% of the company’s stock.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.